The tweet was deleted by the author.
But we saved everything 🙂.
Monte Rosa Therapeutics provided updates on its clinical pipeline and ongoing progress in molecular glue degrader programs during a fireside chat at the Jefferies Global Healthcare Conference in New York.
Chief Medical Officer Filip Janku outlined the company's continued momentum in developing targeted therapies, highlighting the strategy behind their expanding clinical initiatives. The presentation underscores Monte Rosa Therapeutics' commitment to driving innovation in precision medicine.
View post on X Loading...
Monte Rosa Therapeutics has previously highlighted the potential of molecular glue degraders in addressing disease-causing proteins that were considered undruggable, as detailed in a company announcement. The firm also shared plans to discuss new research on molecular glue degraders and cereblon during an Endpoints webinar on May 12. These initiatives reflect Monte Rosa's continued efforts to advance targeted therapies.